Results 61 to 70 of about 4,640 (210)

A functional prognostic model predicts progression‐free survival in patients with relapsed chronic lymphocytic leukemia treated with ibrutinib + venetoclax

HemaSphere, Volume 10, Issue 9, September 2026.
Abstract Targeted therapies have improved outcomes for patients with chronic lymphocytic leukemia (CLL); yet, not all achieve durable responses. Existing prognostic models, developed for chemoimmunotherapy, have limited predictive value for newer targeted combinations.
Johanne U. Hermansen, Weikaixin Kong, Andrea M. Brodersen, Yanping Yin, Aleksandra Urban, Idun D. Rein, Liye He, Rudi Agius, Rebecca S. Teglgaard, Juho Rousu, Christian Brieghel, Sabina Kersting, Mark‐David Levin, Hoa T. T. Tran, Mattias Mattsson, Juha Ranti, Gerrit‐Jan Veldhuis, Caspar da Cunha‐Bang, Rogier Mous, Julie Dubois, Arnon P. Kater, Jorrit M. Enserink, Carsten U. Niemann, Tero Aittokallio, Sigrid S. Skånland   +24 more
wiley   +1 more source

LncRNA HCG11 regulates selinexor sensitivity in multiple myeloma.

Biochemical Pharmacology
Multiple myeloma (MM) is an incurable plasma cell caner featured by monoclonal plasma cell proliferation in bone marrow. The patients inevitably encounter drug resistance and the cancer relapse.
Yue Zhang, Xin Wang, Hongmei Luo, Xiang Liu, Jingcao Huang, Ziyue Mi, Siyao He, Jingjing Wen, Qianwen Gao, Haonan Yang, Yu Feng, Lin-Feng Li, Xinyu Zhai, Fang-Fang Wang, Yang Dai, Li Zhang, Ting Niu, Chun-Yan Sun, Yu-Huan Zheng   +18 more
semanticscholar   +1 more source

The Germline SH2B3rs111340708 Splicing Variant Drives Intron Retention and Protein Instability by Impacting Clinical Outcomes in Core Binding Factor AML

Hematological Oncology, Volume 44, Issue 5, September 2026.
ABSTRACT The SH2B3 gene, also known as LNK, encodes an adaptor protein that negatively regulates key hematopoietic signaling pathways, including JAK–STAT, MAPK, and PI3K/AKT, thereby maintaining hematopoietic homeostasis. SH2B3 interacts with major signaling regulators such as JAK2, MPL, FLT3, and KIT. Loss‐of‐function alterations have been reported in
Marta Rachele Stefanucci, Livia Leuzzi, Linda Montavoci, Davide Paolo Bernasconi, Luca Cimaschi, Alessandra Trojani, Anna Caretti, Lorenzo Del Castello, Roberto Cairoli, Alessandro Beghini   +9 more
wiley   +1 more source

Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia

Pharmaceuticals
Background: Chronic myeloid leukemia is a hematological malignancy characterized by the abnormal proliferation of leukemic cells. Despite significant progress with tyrosine kinase inhibitors, such as Dasatinib, resistance remains a challenge.
Mariarita Spampinato, Tatiana Zuppelli, Ilaria Dulcamare, Lucia Longhitano, Domenico Sambataro, Annalisa Santisi, Amer M. Alanazi, Ignazio A. Barbagallo, Nunzio Vicario, Rosalba Parenti, Alessandra Romano, Giuseppe Musumeci, Giovanni Li Volti, Giuseppe A. Palumbo, Francesco Di Raimondo, Anna Nicolosi, Sebastiano Giallongo, Vittorio Del Fabro   +17 more
doaj   +1 more source

Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody

Cells, 2020
Triple-negative breast cancer (TNBC) is an aggressive disease with poor prognosis and limited therapeutic options. Recent advances in the immunotherapy field have enabled the development of new treatment strategies, among which the use of bispecific ...
Silvia Martini, Mariangela Figini, Aurora Croce, Barbara Frigerio, Marzia Pennati, Alessandro Massimo Gianni, Cinzia De Marco, Maria Grazia Daidone, Christian Argueta, Yosef Landesman, Nadia Zaffaroni, Alessandro Satta   +11 more
doaj   +1 more source

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)

npj Precision Oncology, 2022
Patients with multiple myeloma-bearing translocation t(11;14) have recently been shown to benefit from the apoptosis-inducing drug venetoclax; however, the drug lacks FDA approval in multiple myeloma thus far due to a potential safety signal in the ...
Nina Nguyen, Sana Chaudhry, Tulasigeri M. Totiger, Robert Diaz, Evan Roberts, Skye Montoya, Gabriel Pardo, Alejandro Pardo, Jumana Afaghani, Maurizio Affer, Jacob Jahn, Terrence Bradley, Francesco Maura, Dickran Kazandjian, Daniel Bilbao, Jennifer Chapman, Ola Landgren, James Hoffman, Justin Taylor   +18 more
doaj   +1 more source

Understanding Postmarketing Requirements and Commitments for CYP3A‐Mediated Drug–Drug Interactions: An Analysis of FDA‐Approved Drugs From 2015 to 2024

Clinical and Translational Science, Volume 19, Issue 9, September 2026.
ABSTRACT Addressing knowledge gaps at drug approval through drug–drug interaction (DDI)‐related postmarketing requirements (PMRs) and commitments (PMCs) is essential for safe and effective use. This analysis reviewed CYP3A‐related PMRs and PMCs, the most evaluated enzyme in postmarketing studies, to characterize their scope.
Jingjing Yu, Ichiko Petrie, Sophie Argon, Katie Owens, Isabelle Ragueneau‐Majlessi   +4 more
wiley   +1 more source

Atovaquone and Selinexor as a Novel Combination Treatment Option in Acute Myeloid Leukemia.

Cancer Letters
Acute myeloid leukemia (AML) is the most common acute leukemia and is predominantly affecting older patients. It is a heterogenous disease, showing a broad spectrum of genomic alterations and mutations that influence the clinical outcome and treatment ...
Stefanie Weiss, B. Zdársky, A. Witalisz-Siepracka, S. Edtmayer, A. Holzer, Kerstin Heindl, Emilio Casanova, K. Podar, D. Stoiber   +8 more
semanticscholar   +1 more source

Early‐Phase Research in Pediatric Neuro‐Oncology

Pediatric Blood &Cancer, Volume 73, Issue 10, October 2026.
Jonathan Cunningham
wiley   +1 more source

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma

The FEBS Journal, Volume 293, Issue 17, Page 5121-5139, September 2026.
IMiDs are pivotal in the treatment of multiple myeloma. Mechanisms of resistance comprise cell intrinsic and extrinsic pathways, involving tumour microenvironment, immune cell dysfunction, CRBN‐dependent and independent genetic drivers and epigenetic changes.
Maria‐Cynthia Fuentes‐Lacouture, Devi Nandana, Karthik Ramasamy, Anjan Thakurta   +3 more
wiley   +1 more source